Using Circ-Anapc7 As A Novel Type Of Biomarker In The Monitoring Of Acute Myeloid Leukemia

Ying Shen,Yachun Jia,Ru Zhang,Hongli Chen,Yuandong Feng,Fang-Xia Wang,Wanhong Zhao,Jianli Wang,Aili He,Yun Yang,Yan Xu
DOI: https://doi.org/10.1182/blood-2019-128179
IF: 20.3
2019-01-01
Blood
Abstract:Introduction: Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the clonal proliferation of immature myeloid progenitor cells in the bone marrow, compressing normal blood cell production and leading to bone marrow failure ultimately. Overwhelming evidence has established that non-coding RNAs (ncRNAs), such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) have great role in AML pathogenesis. Circular RNAs (circRNAs) that occupy gene expression at the transcriptional or post-transcriptional level have great potential to be biomarker for types of cancers. We have screened one altered circRNA named circ-ANAPC7 in AML before. In this study, we aimed to validate its expression by enlarging sample size and illuminating the diagnostic and monitoring value of circ-ANAPC7 in AML.
What problem does this paper attempt to address?